<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182167</url>
  </required_header>
  <id_info>
    <org_study_id>20130808</org_study_id>
    <secondary_id>DOH-27-0414-4719.</secondary_id>
    <nct_id>NCT02182167</nct_id>
  </id_info>
  <brief_title>A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis</brief_title>
  <acronym>NAC in TB DIH</acronym>
  <official_title>A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a randomized placebo controlled trial to determine whether administration of
      intravenous (IV) NAC to participants with TB DIH, in dosages similar to that used in
      paracetamol poisoning, can improve recovery from hepatotoxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      South Africa has a huge tuberculosis (TB) disease burden, with 948 per 100 000 people
      diagnosed with TB in 2008. TB drug induced hepatitis (DIH) is a common adverse effect of TB
      therapy that causes significant patient morbidity and prolonged hospital stays.
      N-Acetylcysteine (NAC) has been extensively studied and used for many years in the treatment
      of paracetamol-induced hepatotoxicity, with good evidence of efficacy and safety. NAC has
      also been used in other forms of liver injury and drug toxicity. It has not previously been
      used in the management of TB DIH.

      We will screen all patients with clinical hepatitis on TB treatment admitted to New Somerset
      and Groote Schuur hospitals and aim to recruit 100 participants over 3 years. We will
      randomise 50 participants to receive an IV loading dose of 150mg/kg of NAC over 60 minutes
      followed by 50mg/kg IV over 4 hours by continuous infusion and finally 100mg/kg IV over 16
      hours. Fifty participants will be randomised to receive placebo. The primary outcome will be
      time to normalisation of liver function (ALT&lt;100). We will also determine the effect of NAC
      on duration of hospitalization, rate of recovery from liver failure, all cause mortality, and
      describe adverse effects of IV NAC in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALT normalisation</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on the time to normalization of liver function in patients with TB DIH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery from liver failure</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on the rate of recovery from liver failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on all-cause mortality in patients with TB DIH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the adverse event profile of IV NAC when administered to patients with TB DIH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB Drug Rechallenge</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on success of TB drug rechallenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rechallenge duration</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>To determine the effect of IV NAC on duration of rechallenge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <description>To store blood, urine and biopsy specimens (if biopsies were taken as part of patient management),bank serum, to enable us to conduct future sub studies exploring mechanisms, predictors and biomarkers of TB DIH, genetic associations with TB DIH and improved diagnostic strategies</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Drug-Induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>IV NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .
Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV N-acetylcysteine (NAC)</intervention_name>
    <arm_group_label>IV NAC</arm_group_label>
    <other_name>Paradote</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt; 18 years old

          -  Diagnosed with pulmonary or extrapulmonary tuberculosis based on symptoms,
             radiological features and/or laboratory evidence.

          -  On first line antituberculous therapy

          -  Diagnosed with TB DIH

        Exclusion Criteria:

          -  Patients with a diagnosis of acute viral hepatitis based on a positive anti-HAV, IgM,
             anti- HBcIgM, or confirmed hepatitis C infection

          -  Patients known to be asthmatic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Cohen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Kramer</last_name>
    <email>nicky.kramer@uct.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Cohen</last_name>
    <email>karen.cohen@uct.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Farouk M Chughlay</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mashiko Setshedi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gary Maartens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Sonderup</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wendy Spearman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hannah Gunter</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Somerset Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>8005</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shiraz Moosa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Stead</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Dr Karen Cohen</investigator_full_name>
    <investigator_title>Dr Karen Cohen</investigator_title>
  </responsible_party>
  <keyword>Drug Induced Hepatitis (DIH)</keyword>
  <keyword>Toxic Liver</keyword>
  <keyword>Drug Induced Liver Injury (DILI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Antitubercular Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

